June 8, 2001 — CAMBRIDGE, MA — Biotech developer Genzyme Corp. plans to construct a 300,000 square foot manufacturing facility in Framingham, Mass., along with several other projects as part of a substantial expansion project.

The facility, which will be located near Genzyme’s existing Framingham campus, will support enzyme replacement therapies, monoclonal antibodies, and other recombinant cell-culture products that the company is currently working on.

Construction is slated to begin this fall. Officials expect the site to be operational by 2004.

The company is also working to establish a manufacturing facility in Ireland after recently buying a 120,000 square foot facility located on 32-acre site in Waterford. The site is expected to be operational by the middle of 2003 and will be used to produce Renagel (sevelamer hydrochloride), a phosphate binder for dialysis patients.

Genzyme also plans to establish a multi-product manufacturing center in Waterford that will include a bulk pharmaceutical manufacturing facility, a biologics fill and a finishing plant to support protein and antibody products.

Finally, the company is in the middle of expansion of its manufacturing facility in Haverhill, England, that will significantly increase the site’s production capacity.